The FDA had previously approved Pfizer's Abrysvo vaccine only for use in older adults. Adults ages 60 and older are recommended to talk to their doctors about potentially getting the shot.

By the second half of 2024, Abrysvo had a 48% share in pharmacies and other locations, Pfizer said. Abrysvo sales have pulled ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown its staying power in older adults who received a single dose before the previous virus season. In season two, Abrysvo was 78% ...

Pfizer is also evaluating Abrysvo in children aged between two and 17 years in an open-label Phase I PICASSO trial (NCT05900154). The trial enrolled 128 participants across the US, according to ...

Pfizer Inc. today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial MONeT, evaluating two doses of ABRYSVO vaccine in ...

Abrysvo is made by Pfizer. The Food and Drug Administration (FDA) has approved the first vaccine for pregnant women to prevent RSV in infants, the agency announced on Monday.

ABRYSVO was tested in a clinical trial with an estimated 37,000 participants, according to a press release from Pfizer. It is expected to be available ahead of the next peak RSV season in the fall.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), ...

Pfizer’s MONeT study looked at Abrysvo’s performance across two subgroups. The trial enrolled 681 adults with chronic medical conditions for substudy A, plus another 200 who were ...

Tuesday, Pfizer Inc PFE released top-line immunogenicity and safety data from the ongoing pivotal Phase 3 MONeT trial, evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years ...